You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020150019
Dec 202052010
Jan 202191023
Feb 202178021
Mar 2021134021
Apr 2021176032
May 202178024
Jun 20210021
Jul 20211019
Aug 20211034
Sep 20210031
Oct 2021114038
Nov 202174032
Dec 2021122015
Jan 202292016
Feb 202285017
Mar 2022114020
Apr 2022128018
May 2022126024
Jun 202293029
Jul 202264020
Aug 2022112030
Sep 20226408
Oct 2022161024
Nov 2022102014
Dec 20226803
Jan 202354010
Feb 20234605
Mar 20237408
Apr 20234607
May 20235003
Jun 20234207
Jul 20234004
Aug 20236008
Sep 20233208
Oct 20233604
Nov 20236206
Dec 20237206
Jan 20245603
Feb 202474012
Mar 20244804
Apr 20244207
May 20244400
Jun 20245004
Jul 202444012
Aug 20243206
Sep 20243403
Oct 202444010
Nov 20245406
Dec 20246609
Jan 202556019
Feb 202538018
Mar 20250013
Apr 2025004
May 2025009
Jun 2025004
Total35760782